Hims & Hers Built a Billion-Dollar Business on a Loophole. The FDA Just Closed It.

---

To understand what just happened to Hims & Hers, you have to understand the specific, narrow, and temporary
regulatory window that its weight-loss business was built inside. When the U.S. Food and Drug Administration
formally declares a drug to be in shortage, it activates a provision of federal law that allows compounding
pharmacies — facilities that custom-mix medications — to produce their own versions of the drug to meet patient
demand the manufacturer cannot supply. The blockbuster GLP-1 weight-loss drugs, Novo Nordisk's semaglutide
(Wegovy, Ozempic) and Eli Lilly's tirzepatide (Zepbound, Mounjaro), were in exactly such a shortage as demand
exploded far beyond what the manufacturers could produce. And so, perfectly legally, compounding pharmacies were
permitted to make copies — and Hims & Hers built a large, fast-growing, high-margin business selling compounded
semaglutide directly to consumers through its telehealth platform.

It was, for a while, a spectacular business. Compounded semaglutide could be sold at a fraction of the branded
drug's list price while still carrying fat margins for Hims, because the company controlled the whole funnel —
the online consultation, the prescription, the pharmacy, the subscription. Customers got a cheap version of the
most sought-after drug in the country; Hims got a high-margin, recurring-revenue product riding the biggest
consumer-health trend in a generation. The stock soared as the company's revenue and profits surged, and Wall
Street re-rated Hims from a niche purveyor of hair-loss and erectile-dysfunction treatments into a disruptive
weight-loss powerhouse.

There was only one problem, and it was structural rather than operational: the entire weight-loss business
depended on the drug remaining in shortage. The shortage was the legal foundation. And shortages, by their
nature, end.

When the shortage ended, the business became illegal

This is the hinge of the whole story, and it is worth stating with precision. The legal permission to compound
copies of semaglutide and tirzepatide existed only because the drugs were in FDA-declared shortage. As Novo
Nordisk and Eli Lilly ramped manufacturing and the shortages were resolved, the FDA removed the drugs from its
shortage list — and the moment it did, the legal basis for mass-compounding copies evaporated. What had been a
booming, legitimate business one quarter became, the next, a practice the FDA was moving to shut down. The agency
set wind-down deadlines for compounding pharmacies to stop producing copies, and the window that had made Hims's
weight-loss business possible swung shut.

Hims did not go quietly, and its response is the most revealing part of the episode. Rather than exit the
business when the shortage ended, the company leaned on what came to be called the "personalization loophole" —
the argument that its formulations were not "essentially copies" of the branded drugs because they had been
modified, most commonly by adding ingredients like B vitamins to the semaglutide. Under the rules, a compounding
pharmacy can make a personalized version of a commercially available drug if a prescriber documents that the
modification produces a clinically "significant difference" needed for that specific patient. Hims's bet was that
adding a vitamin to a mass-marketed weight-loss injection cleared that bar.

The FDA and the drug makers did not agree, and the regulatory response was severe. In early 2026 federal regulators moved to
restrict the active ingredients used in compounded GLP-1s and, in a striking escalation, the Department of Health
and Human Services' general counsel announced a referral of Hims & Hers to the Department of Justice for
potential violations of the Federal Food, Drug, and Cosmetic Act. Days later, Novo Nordisk sued the company for
patent infringement over both its compounded semaglutide pill and its injectable. The
"personalization" defense — adding B12 to a drug and calling it bespoke medicine — was precisely the kind of
fig leaf that regulators exist to tear off, and they tore it off. What the bull narrative had treated as a
durable, innovative weight-loss platform was revealed to be, in significant part, a business operating in a
gray zone that the law was always going to close.

The pivot that proves the point

Faced with the closing of the loophole, Hims did the only thing it could: it pivoted from selling cheap compounded
copies to reselling the expensive branded drugs, striking arrangements to offer FDA-approved Wegovy and
Zepbound to its 2.6 million subscribers. Management framed this as a maturation — a move from the gray market to
legitimate partnership with the manufacturers. And as a matter of legal hygiene, it is. But as a matter of
business economics, the pivot is a confession, and the income statement spells it out.

Look at what happened to the financials the moment the compounded business gave way to the branded one. In the
first quarter of 2026, Hims's gross margin collapsed to 65% from 73% a year earlier — an eight-point compression
that management directly attributed to the shift away from compounded semaglutide. The company swung from $49.5
million of net income in the prior-year quarter to a net loss of $92.1 million, weighed down by roughly $33.5
million of restructuring charges and a $15 million legal settlement tied to the GLP-1 transition. And most
tellingly, revenue grew just 4% year over year, to $608 million — a stunning deceleration for a company whose
stock had been priced for sustained hyper-growth.

Each of those numbers points to the same truth: the compounded GLP-1 business was Hims's high-margin growth
engine, and replacing it with branded reselling is replacing a high-margin product with a low-margin one. When
you sell a branded drug, you are a reseller taking a thin cut, competing with every pharmacy in America, with the
manufacturer setting the price and capturing most of the value. When you compound your own copy, you control the
margin. The 73%-to-65% gross-margin collapse is the mathematical signature of that downgrade, and the 4% revenue
growth is the signature of a growth engine that has lost its fuel. The pivot did not strengthen the business. It
revealed how much of the business's quality had depended on the loophole.

What the bulls genuinely get right

In fairness — and it matters, because Hims is not a one-trick company and the bear case can be overstated — there
is a real and reasonable bull argument, and several of its pillars are sound.

First and most important, Hims & Hers is genuinely diversified beyond GLP-1s. The majority of its 2025 revenue
came from non-weight-loss categories — hair loss, erectile dysfunction, mental health, dermatology, sexual
health — a broad menu of recurring-subscription consumer-health products served to a large and growing base of
2.6 million subscribers. That base is a real asset: a direct relationship with millions of customers who have
demonstrated willingness to pay monthly for convenient, destigmatized telehealth. The weight-loss loophole
closing damages one product line; it does not erase the platform. Second, management raised full-year 2026
revenue guidance to a range of $2.8–3.0 billion, signaling confidence that the branded-GLP-1 transition and the
rest of the business can keep the top line growing despite the compounded headwind. Third, there are genuine new
avenues: the new partnerships with Novo Nordisk and Eli Lilly give Hims a legitimate, sanctioned weight-loss
offering, and an evolving regulatory attitude toward peptides under the current administration could open fresh,
higher-margin categories over time.

The honest synthesis is that Hims & Hers is a real, durable consumer-health platform that happened to ride a
temporary regulatory loophole to a valuation that priced the loophole's economics as permanent. The platform
survives; the specific high-margin engine that drove the parabolic re-rating does not. The bulls are right that
the company isn't dying. The question the $608 million quarter answers is whether it deserves a hyper-growth,
high-margin multiple now that the hyper-growth, high-margin product is gone — and the 4% growth and the
eight-point margin compression strongly suggest the answer is no.

Why the regulators actually cared

It is worth pausing on why the FDA moved so aggressively, because it reframes the loophole closing from
arbitrary bureaucratic interference — the way some bulls have characterized it — into a predictable response to a
genuine concern, which makes its permanence more certain. Compounded drugs are not subject to the same
pre-market approval, manufacturing oversight, and quality control as FDA-approved branded medications. They are
mixed by pharmacies, and the active ingredients can come from sources of varying quality. When such compounding
is confined to its intended purpose — filling a genuine, individualized gap a manufacturer cannot meet — the
trade-off is acceptable. When it scales into a mass-market operation shipping hundreds of thousands of doses of a
powerful injectable drug, the safety calculus changes, and regulators take notice of dosing errors, ingredient
sourcing, and the absence of the controls that govern the branded product.

That is the substantive reason the closing of the loophole is durable rather than negotiable: it is not merely
that Hims's "personalization" argument was legally thin, but that the underlying policy direction — restricting
mass-compounding of complex injectables once the shortage justification disappears — reflects a real and
defensible safety priority that the drug manufacturers, with their enormous lobbying weight and legitimate
patent and quality interests, are aligned in defending. When the regulator's safety concern, the law's plain
text, and the deep pockets of Novo Nordisk and Eli Lilly all point the same direction, the gray-market window
does not reopen. An investor hoping the enforcement is a passing storm that Hims can wait out is betting against
the most durable alignment of interests in the entire episode. The arbitrage is not closed temporarily. It is
closed structurally.

What "telehealth reseller" is worth

Strip the narrative to its economics and the valuation question becomes stark. Before the loophole closed, the
market valued Hims as a high-margin, hyper-growth disruptor — a company compounding revenue at rates north of
50% with gross margins in the low-to-mid seventies, riding the defining consumer-health trend of the decade. That
is a profile that justifies a rich multiple. After the loophole closed, the company that remains grows its top
line at 4%, carries gross margins compressed to 65% and falling as branded reselling mixes in, posts net losses
during the transition, and faces a legal overhang — a profile that justifies a far more modest one.

The danger for the stock is that these two descriptions are of the same company, and the market has been slow
to swap the first multiple for the second. A consumer-subscription health platform reselling other companies'
drugs at thin margins, alongside a stable but unspectacular menu of hair-loss and wellness products, is a
perfectly good business — but it is a different kind of business, worth a different kind of money, than the
weight-loss disruptor the stock was priced to be. The gap between those two valuations is the risk, and it is the
same risk that runs under several stories in this series: a multiple set during an extraordinary, unrepeatable
period, applied to a company whose extraordinary period has ended. The branded partnerships and the peptide
optionality may, over time, build new high-margin engines to replace the lost one. But "may, over time" is a
venture proposition, and the stock is still carrying, in part, a price set for a certainty that has already
expired. The market will eventually mark the business to what it now is rather than what it briefly was, and the
distance between those two figures is the unpriced downside.

The legal overhang nobody is pricing

There is one more element the valuation seems to wave past, and it deserves explicit, carefully-labeled
attention: the legal and regulatory overhang. A DOJ referral is not a conviction, and Novo Nordisk's litigation
is not an adjudicated finding — these are allegations and processes, not verdicts, and Hims is entitled to defend
itself and may well prevail. Intellectual honesty requires saying so clearly.

But a company that has been referred to the Department of Justice for potential federal violations and is being
sued for patent infringement by one of the largest pharmaceutical companies in the world over its core former
product — the same company it is now also partnering with to resell branded drugs, an awkwardness that captures
the whole strange situation — is carrying a tail risk that a clean consumer-health platform does not. The range of outcomes includes settlements, penalties,
injunctions, and reputational damage, and even if each individual adverse outcome is unlikely, their cumulative
weight is a real cost that an investor must price. The market, in its enthusiasm for the GLP-1 story and the
pivot narrative, has shown a tendency to treat the legal overhang as noise. It is not noise. It is the
predictable consequence of having built a business in a gray zone — the bill that arrives after the loophole
party ends, and one that does not appear on any quarter's revenue line but hangs over every future one.

The pattern: a business model that was really a regulatory arbitrage

Step back and the Hims episode fits a recognizable and instructive pattern: the company that mistakes a
regulatory arbitrage for a durable business model. The compounding-during-shortage provision was never intended
as a permanent commercial opportunity; it was a safety valve to ensure patients could get medicine during a
supply crisis. Hims, cleverly and lucratively, built a large business inside that safety valve — and for a while
the market rewarded it as though the arbitrage were a moat. But a regulatory arbitrage is the opposite of a moat.
A moat is a durable advantage competitors cannot cross; an arbitrage is a temporary gap that the rule-makers will
eventually close, precisely because it was never meant to be a business in the first place.

The tell, in retrospect, was always the dependence on the shortage. A business whose existence requires a
specific drug to remain unavailable from its manufacturer is a business betting against the manufacturer solving
its own supply problem — and betting against a company like Novo Nordisk or Eli Lilly ramping production of its
most profitable product in history is not a bet that ages well. The shortage was always going to end, because the
manufacturers had every incentive on Earth to end it. When it did, the arbitrage closed, and what was left was a
telehealth reseller with a diversified but lower-margin business, a decelerating top line, and a legal cloud. The
market had been pricing the arbitrage as if it were the company. The arbitrage was just the weather.

The kicker

The most seductive businesses are the ones that look like disruptive innovation but are actually regulatory
timing — companies that found a temporary gap between what the rules permit and what the rules intend, and
monetized it brilliantly until the gap closed. Hims & Hers found such a gap in the FDA's shortage provisions, and
for two years it was one of the great growth stories in consumer health, and the stock was priced as though the
growth and the margins would last forever. They could not last, because they were never the company's to keep —
they belonged to a shortage that the world's largest drug makers were racing to eliminate. Now the shortage is
gone, the copies are illegal, the margins have compressed, the growth has stalled, the DOJ has been called, and
Hims is left selling other companies' drugs at other companies' margins to the subscriber base it built on a
window that has closed.

There is a broader lesson here for the entire telehealth-meets-pharma gold rush that the GLP-1 era spawned. A
great many companies have rushed to monetize the weight-loss boom, and the ones built on durable foundations —
genuine manufacturing, real patents, sanctioned distribution — will endure, while the ones built on timing and
gray zones will discover, as Hims has, that the rules eventually catch up with the cleverness. The market is
notoriously bad at distinguishing the two in real time, because during the boom they look identical: both grow
fast, both make money, both tell a thrilling story. The difference only becomes visible when the regulatory tide
goes out, and then it becomes the only thing that matters. Hims is the first big name to be caught swimming as
the water receded; it will not be the last, and the ones holding the richest loophole-era multiples have the
furthest to fall.

The best product Hims ever sold was a loophole, and loopholes are not assets — they are borrowed time. The
shortage that built the business was always going to end, because the only people who could end it were the ones
losing billions while it lasted. It ended. The margin went with it, the growth went with it, and what remained
was the bill, addressed to whoever still owned the stock at loophole prices.